Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 62

1.

Androgen suppresses the proliferation of androgen receptor-positive castration-resistant prostate cancer cells via inhibition of Cdk2, CyclinA, and Skp2.

Kokontis JM, Lin HP, Jiang SS, Lin CY, Fukuchi J, Hiipakka RA, Chung CJ, Chan TM, Liao S, Chang CH, Chuu CP.

PLoS One. 2014 Oct 1;9(10):e109170. doi: 10.1371/journal.pone.0109170. eCollection 2014. Erratum in: PLoS One. 2014;9(10):e111731.

2.

Cholestane-3β, 5α, 6β-triol suppresses proliferation, migration, and invasion of human prostate cancer cells.

Lin CY, Huo C, Kuo LK, Hiipakka RA, Jones RB, Lin HP, Hung Y, Su LC, Tseng JC, Kuo YY, Wang YL, Fukui Y, Kao YH, Kokontis JM, Yeh CC, Chen L, Yang SD, Fu HH, Chen YW, Tsai KK, Chang JY, Chuu CP.

PLoS One. 2013 Jun 13;8(6):e65734. doi: 10.1371/journal.pone.0065734. Print 2013.

3.

Caffeic acid phenethyl ester suppresses the proliferation of human prostate cancer cells through inhibition of p70S6K and Akt signaling networks.

Chuu CP, Lin HP, Ciaccio MF, Kokontis JM, Hause RJ Jr, Hiipakka RA, Liao S, Jones RB.

Cancer Prev Res (Phila). 2012 May;5(5):788-97. doi: 10.1158/1940-6207.CAPR-12-0004-T.

4.

Androgens as therapy for androgen receptor-positive castration-resistant prostate cancer.

Chuu CP, Kokontis JM, Hiipakka RA, Fukuchi J, Lin HP, Lin CY, Huo C, Su LC.

J Biomed Sci. 2011 Aug 23;18:63. doi: 10.1186/1423-0127-18-63. Review.

5.

Androgen suppresses proliferation of castration-resistant LNCaP 104-R2 prostate cancer cells through androgen receptor, Skp2, and c-Myc.

Chuu CP, Kokontis JM, Hiipakka RA, Fukuchi J, Lin HP, Lin CY, Huo C, Su LC, Liao S.

Cancer Sci. 2011 Nov;102(11):2022-8. doi: 10.1111/j.1349-7006.2011.02043.x. Epub 2011 Aug 18. Erratum in: Cancer Sci. 2013 Jan;104(1):142. Huo, Chiech [corrected to Huo, Chieh].

6.

The effect of diet on the response of low-density lipoprotein receptor knockout mice to the liver X receptor agonist T1317.

Peng L, Hiipakka RA, Xie JT, Kokontis JM, Liao S, Peng D.

J Cardiovasc Pharmacol. 2011 Jul;58(1):102-10. doi: 10.1097/FJC.0b013e31821d1168.

PMID:
21558881
7.

A novel potent synthetic steroidal liver X receptor agonist lowers plasma cholesterol and triglycerides and reduces atherosclerosis in LDLR(-/-) mice.

Peng D, Hiipakka RA, Xie JT, Dai Q, Kokontis JM, Reardon CA, Getz GS, Liao S.

Br J Pharmacol. 2011 Apr;162(8):1792-804. doi: 10.1111/j.1476-5381.2011.01202.x.

8.

Synthesis and structure-activity relationship of 3-O-acylated (-)-epigallocatechins as 5α-reductase inhibitors.

Lin SF, Lin YH, Lin M, Kao YF, Wang RW, Teng LW, Chuang SH, Chang JM, Yuan TT, Fu KC, Huang KP, Lee YS, Chiang CC, Yang SC, Lai CL, Liao CB, Chen P, Lin YS, Lai KT, Huang HJ, Yang JY, Liu CW, Wei WY, Chen CK, Hiipakka RA, Liao S, Huang JJ.

Eur J Med Chem. 2010 Dec;45(12):6068-76. doi: 10.1016/j.ejmech.2010.10.011. Epub 2010 Oct 15.

PMID:
21044810
9.

Differential effects of activation of liver X receptor on plasma lipid homeostasis in wild-type and lipoprotein clearance-deficient mice.

Peng D, Hiipakka RA, Xie JT, Reardon CA, Getz GS, Liao S.

Atherosclerosis. 2010 Jan;208(1):126-33. doi: 10.1016/j.atherosclerosis.2009.07.016. Epub 2009 Jul 8.

10.

Suppression of androgen receptor signaling and prostate specific antigen expression by (-)-epigallocatechin-3-gallate in different progression stages of LNCaP prostate cancer cells.

Chuu CP, Chen RY, Kokontis JM, Hiipakka RA, Liao S.

Cancer Lett. 2009 Mar 8;275(1):86-92. doi: 10.1016/j.canlet.2008.10.001. Epub 2008 Nov 1.

11.

Antiatherosclerotic effects of a novel synthetic tissue-selective steroidal liver X receptor agonist in low-density lipoprotein receptor-deficient mice.

Peng D, Hiipakka RA, Dai Q, Guo J, Reardon CA, Getz GS, Liao S.

J Pharmacol Exp Ther. 2008 Nov;327(2):332-42. doi: 10.1124/jpet.108.142687. Epub 2008 Aug 22.

12.

Differential anti-atherosclerotic effects in the innominate artery and aortic sinus by the liver X receptor agonist T0901317.

Peng D, Hiipakka RA, Reardon CA, Getz GS, Liao S.

Atherosclerosis. 2009 Mar;203(1):59-66. doi: 10.1016/j.atherosclerosis.2008.05.058. Epub 2008 Jun 12.

13.

Molecular mechanism of androgen action.

Hiipakka RA, Liao S.

Trends Endocrinol Metab. 1998 Oct 1;9(8):317-24.

PMID:
18406296
14.

The liver X receptor agonist T0901317 acts as androgen receptor antagonist in human prostate cancer cells.

Chuu CP, Chen RY, Hiipakka RA, Kokontis JM, Warner KV, Xiang J, Liao S.

Biochem Biophys Res Commun. 2007 Jun 1;357(2):341-6. Epub 2007 Mar 28.

15.
16.

Modulation of liver X receptor signaling as novel therapy for prostate cancer.

Chuu CP, Kokontis JM, Hiipakka RA, Liao S.

J Biomed Sci. 2007 Sep;14(5):543-53. Epub 2007 Mar 20. Review.

PMID:
17372849
17.

Inhibition of tumor growth and progression of LNCaP prostate cancer cells in athymic mice by androgen and liver X receptor agonist.

Chuu CP, Hiipakka RA, Kokontis JM, Fukuchi J, Chen RY, Liao S.

Cancer Res. 2006 Jul 1;66(13):6482-6.

18.

Role of androgen receptor in the progression of human prostate tumor cells to androgen independence and insensitivity.

Kokontis JM, Hsu S, Chuu CP, Dang M, Fukuchi J, Hiipakka RA, Liao S.

Prostate. 2005 Dec 1;65(4):287-98.

PMID:
16015608
19.

5beta-Cholane activators of the farnesol X receptor.

Fukuchi J, Song C, Dai Q, Hiipakka RA, Liao S.

J Steroid Biochem Mol Biol. 2005 Mar;94(4):311-8. Epub 2005 Feb 5.

PMID:
15857750
20.
21.

Antiproliferative effect of liver X receptor agonists on LNCaP human prostate cancer cells.

Fukuchi J, Kokontis JM, Hiipakka RA, Chuu CP, Liao S.

Cancer Res. 2004 Nov 1;64(21):7686-9.

22.

Androgenic suppression of ATP-binding cassette transporter A1 expression in LNCaP human prostate cancer cells.

Fukuchi J, Hiipakka RA, Kokontis JM, Hsu S, Ko AL, Fitzgerald ML, Liao S.

Cancer Res. 2004 Nov 1;64(21):7682-5.

23.

TATA-binding protein-associated factor 7 regulates polyamine transport activity and polyamine analog-induced apoptosis.

Fukuchi J, Hiipakka RA, Kokontis JM, Nishimura K, Igarashi K, Liao S.

J Biol Chem. 2004 Jul 16;279(29):29921-9. Epub 2004 Apr 12.

24.

Structure-activity relationships for inhibition of human 5alpha-reductases by polyphenols.

Hiipakka RA, Zhang HZ, Dai W, Dai Q, Liao S.

Biochem Pharmacol. 2002 Mar 15;63(6):1165-76.

PMID:
11931850
25.

Growth suppression of hamster flank organs by topical application of catechins, alizarin, curcumin, and myristoleic acid.

Liao S, Lin J, Dang MT, Zhang H, Kao YH, Fukuchi J, Hiipakka RA.

Arch Dermatol Res. 2001 Apr;293(4):200-5.

PMID:
11380153
26.

Green tea: biochemical and biological basis for health benefits.

Liao S, Kao YH, Hiipakka RA.

Vitam Horm. 2001;62:1-94. Review. No abstract available.

PMID:
11345896
28.

Modulation of obesity by a green tea catechin.

Kao YH, Hiipakka RA, Liao S.

Am J Clin Nutr. 2000 Nov;72(5):1232-4. No abstract available.

PMID:
11063454
29.

Selective activation of liver X receptor alpha by 6alpha-hydroxy bile acids and analogs.

Song C, Hiipakka RA, Liao S.

Steroids. 2000 Aug;65(8):423-7.

PMID:
10936612
30.

Modulation of endocrine systems and food intake by green tea epigallocatechin gallate.

Kao YH, Hiipakka RA, Liao S.

Endocrinology. 2000 Mar;141(3):980-7.

PMID:
10698173
31.

Rat and human maspins: structures, metastatic suppressor activity and mutation in prostate cancer cells.

Umekita Y, Hiipakka RA, Liao S.

Cancer Lett. 1997 Feb 26;113(1-2):87-93.

PMID:
9065806
32.

Human prostate tumor growth in athymic mice: inhibition by androgens and stimulation by finasteride.

Umekita Y, Hiipakka RA, Kokontis JM, Liao S.

Proc Natl Acad Sci U S A. 1996 Oct 15;93(21):11802-7.

33.

Growth inhibition and regression of human prostate and breast tumors in athymic mice by tea epigallocatechin gallate.

Liao S, Umekita Y, Guo J, Kokontis JM, Hiipakka RA.

Cancer Lett. 1995 Sep 25;96(2):239-43.

PMID:
7585463
34.
35.

Ubiquitous receptor: structures, immunocytochemical localization, and modulation of gene activation by receptors for retinoic acids and thyroid hormones.

Song C, Hiipakka RA, Kokontis JM, Liao S.

Ann N Y Acad Sci. 1995 Jun 12;761:38-49. Review. No abstract available.

PMID:
7625741
36.

Assignment of the human ubiquitous receptor gene (UNR) to 19q13.3 using fluorescence in situ hybridization.

Le Beau MM, Song C, Davis EM, Hiipakka RA, Kokontis JM, Liao S.

Genomics. 1995 Mar 1;26(1):166-8. No abstract available.

PMID:
7782080
37.

Ubiquitous receptor: a receptor that modulates gene activation by retinoic acid and thyroid hormone receptors.

Song C, Kokontis JM, Hiipakka RA, Liao S.

Proc Natl Acad Sci U S A. 1994 Nov 8;91(23):10809-13.

38.
39.

The androgen receptor status of neuroendocrine cells in human benign and malignant prostatic tissue.

Nakada SY, di Sant'Agnese PA, Moynes RA, Hiipakka RA, Liao S, Cockett AT, Abrahamsson PA.

Cancer Res. 1993 May 1;53(9):1967-70.

40.

Immunocytochemical localization of androgen receptors in human skin using monoclonal antibodies against the androgen receptor.

Liang T, Hoyer S, Yu R, Soltani K, Lorincz AL, Hiipakka RA, Liao S.

J Invest Dermatol. 1993 May;100(5):663-6.

42.

Prostatic ductal system in rats: regional variation in morphological and functional activities.

Lee C, Sensibar JA, Dudek SM, Hiipakka RA, Liao ST.

Biol Reprod. 1990 Dec;43(6):1079-86.

PMID:
2291926
43.

Anti-5 alpha-reductase autoantibodies in the serum of patients with prostatic cancer.

Liang T, Hiipakka RA, Stebbins J, Liao S.

J Clin Endocrinol Metab. 1990 Dec;71(6):1666-8.

PMID:
2229323
45.

Androgen receptors: structures, mutations, antibodies and cellular dynamics.

Liao SS, Kokontis J, Sai T, Hiipakka RA.

J Steroid Biochem. 1989;34(1-6):41-51.

PMID:
2626035
46.
47.

Correction of the cDNA-derived protein sequence of prostatic spermine binding protein: pivotal role of tandem mass spectrometry in sequence analysis.

Anderegg RJ, Carr SA, Huang IY, Hiipakka RA, Chang CS, Liao ST.

Biochemistry. 1988 Jun 14;27(12):4214-21.

PMID:
3166977
48.

Steroid receptor recycling and interaction of receptor with RNA.

Hiipakka RA, Liao S.

Am J Clin Oncol. 1988;11 Suppl 2:S18-22. Review.

PMID:
2468270
49.

Identification of glutathione S-transferase Yb1 mRNA as the androgen-repressed mRNA by cDNA cloning and sequence analysis.

Chang CS, Saltzman AG, Sorensen NS, Hiipakka RA, Liao SS.

J Biol Chem. 1987 Sep 5;262(25):11901-3.

50.

Prostatic spermine-binding protein. Cloning and nucleotide sequence of cDNA, amino acid sequence, and androgenic control of mRNA level.

Chang CS, Saltzman AG, Hiipakka RA, Huang IY, Liao SS.

J Biol Chem. 1987 Feb 25;262(6):2826-31.

Supplemental Content

Loading ...
Support Center